Ken Griffin Repligen Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$119.79 - $167.35 $730,719 - $1.02 Million	6,100 Added 48.8%	18,600 $2.77 Million
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $4.15 Million - $6.33 Million	-34,600 Reduced 73.46%	12,500 $1.58 Million
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $4.25 Million - $5.19 Million	24,900 Added 112.16%	47,100 $8.66 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $924,777 - $1.5 Million	8,100 Added 57.45%	22,200 $3.99 Million
Q3 2023 Nov 14, 2023	SELL	$138.78 - $176.51 $3.84 Million - $4.89 Million	-27,700 Reduced 66.27%	14,100 $2.24 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $2.8 Million - $3.64 Million	20,200 Added 93.52%	41,800 $5.91 Million
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $2.14 Million - $2.75 Million	-13,900 Reduced 39.15%	21,600 $3.64 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $600,954 - $816,072	3,700 Added 11.64%	35,500 $6.01 Million
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $914,393 - $1.46 Million	5,700 Added 21.84%	31,800 $5.95 Million

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.